Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2

Two adenocarcinoma cell lines, Breast M25-SF and Breast M, were established from tumor tissue resected surgically from a patient with breast cancer. One, Breast M25-SF, expresses interleukin-2 receptor (IL-2R) on the cell surface and the other, Breast M, does not. The effects of recombinant inteleukin-2 (rIL-2) on the proliferation of these cell lines were investigated. The growth of Breast M25-SF was significantly promoted by rIL-2 ranging from 1,25 U/ml to 640 U/ml. Anti-CD25 (Tac) antibody, significantly blocked the growth enhancement of Breast M25-SF by rIL-2. Breast M, however, did not respond to rIL-2. To confirm more directly the promotion of Breast M25-SF growth by rIL-2, cloning of IL-2 responders from parent Breast M25-SF cells was carried out by limiting dilution without feeder cells in 96-well microplates. No colony formation was found in 24 wells without rIL-2. Eleven, 13 and 6 clones were established from groups of 24 wells containing rIL-2 at 200, 20 and 2 U/ml respectively. All of the clones expressed IL-2R and respond to rIL-2. By using a sensitive polymerase chain reaction technique, we demonstrated that Breast M25-SF but not Breast M expressed IL-2 mRNA, and IL-2 secretion from Breast M25-SF but not Breast M was also confirmed by radioimmunoassay. These findings suggest a role for IL-2 in autocrine support of Breast M25-SF growth. IL-2 may play an important role in the growth control of breast carcinoma cells.

[1]  A. Albino,et al.  Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. , 1991, Cancer research.

[2]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[3]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[4]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[5]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[6]  G. Marti,et al.  Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. , 1989, Blood.

[7]  T. Waldmann,et al.  trans activation of granulocyte-macrophage colony-stimulating factor and the interleukin-2 receptor in transgenic mice carrying the human T-lymphotropic virus type 1 tax gene , 1989, Molecular and cellular biology.

[8]  H. Paterson,et al.  N-ras dependent revertant phenotype in human HT1080 fibrosarcoma cells is associated with loss of proliferation within normal tissues and expression of an adult membrane antigenic phenotype. , 1989, Oncogene.

[9]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[10]  R. Knobler,et al.  Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Luger,et al.  IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. , 1989, Journal of immunology.

[12]  S. Rosenberg,et al.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2 , 1984, The Journal of experimental medicine.

[13]  T. Loucks,et al.  Correlation between human cell growth response to interleukin 1 and receptor binding. , 1988, Cancer research.

[14]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[15]  S. Rosenberg,et al.  Lymphokine-Activated Killer Cells , 1989 .

[16]  V. Georgoulias,et al.  Presence of a p70 IL-2-binding peptide on leukemic cells from various hemopoietic lineages. , 1989, Journal of immunology.

[17]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[18]  J. Johnson,et al.  Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. , 1992, Cancer research.

[19]  T. Hirano,et al.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Morton,et al.  Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. , 1993, Cancer research.

[21]  C. Jasmin,et al.  Expression of the interleukin-2 receptor on human fibroblasts and its biological significance. , 1992, International immunology.

[22]  L. Tamarkin,et al.  Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo. , 1988, Anticancer research.

[23]  U. Renner,et al.  Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. , 1992, The Journal of clinical investigation.

[24]  G. Marti,et al.  Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies , 1989 .

[25]  K. Kawahara,et al.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. , 1985, Biochemical and biophysical research communications.

[26]  M. Doyle,et al.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.

[27]  S. Rosenberg,et al.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. , 1984, Cancer research.